Opinion

Video

Relapsed/Refractory DLBCL: Therapeutic Options in the Third Line Setting

Author(s):

Sonali Smith, MD,Krish Patel, MD

Focusing their discussion on therapeutic options for patients with R/R DLBCL, in the third line and beyond setting.

Related Videos
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
November 15th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

FDA
November 14th 2024

FDA Approves Nilotinib Tablets Without Mealtime Restrictions for CML

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Jennifer Amengual, MD, Herbert Irving Assistant Professor of Medicine, Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
November 13th 2024

Real-World Experience With CAR T Varies From Trials in DLBCL

Revumenib in NPM1+ R/R AML | Image Credit: © LASZLO– stock.adobe.com
November 12th 2024

Revumenib Meets CR/CRh End Point in NPM1+ R/R AML